Go All-In On Actavi...
Health Care: Drugs
Vermillion Inc. (VRML: NASDAQ)
$2.77 -0.02 | -0.72%
06/18/13 - 03:59 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 2.09M | 1.92M | 1.18M | 0.00 |
| Cost of Sales | 45.00K | 52.00K | 88.00K | 0.00 |
| Gross Operating Profit | 2.05M | 1.87M | 1.09M | 0.00 |
| Selling, General, and Administrative Expenses | 9.16M | 14.05M | 11.84M | 3.02M |
| Research & Development | 2.22M | 5.39M | 3.85M | 2.35M |
| Operating Income before D & A (EBITDA) | -9.33M | -17.56M | -14.60M | -5.36M |
| Depreciation & Amortization | 86.00K | 77.00K | 114.00K | 417.00K |
| Interest Income | 28.00K | 64.00K | 40.00K | 28.00K |
| Other Income - Net | 2.45M | 183.00K | -3.98M | -15.01M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -6.94M | -17.39M | -18.66M | -20.76M |
| Interest Expense | 206.00K | 396.00K | 491.00K | 1.69M |
| Pre-Tax Income | -7.15M | -17.79M | -19.15M | -22.45M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 11.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -7.15M | -17.79M | -19.03M | -22.05M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -7.15M | -17.79M | -19.03M | -22.05M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -7.15M | -17.79M | -19.03M | -22.05M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-7.15M | -17.79M | -19.03M | -22.05M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -7.15M | -17.79M | -19.03M | -22.05M |
| Basic EPS from Continuing Ops. | -0.48 | -1.25 | -1.83 | -3.31 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.48 | -1.25 | -1.83 | -3.31 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.48 | -1.25 | -1.83 | -3.31 |
| Basic Normalized Net Income/Share | -0.48 | -1.25 | -1.83 | -3.31 |
| EPS fr Continuing Ops. | -0.48 | -1.25 | -1.83 | -3.31 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.48 | -1.25 | -1.83 | -3.31 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.48 | -1.25 | -1.83 | -3.31 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.48 | -1.25 | -1.83 | -3.31 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with VRML
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor5 Drug Stock Losers of 2010
- UserDNC Portfolio 1
Latest VRML Headlines from TheStreet
- Vermillion Management Discusses Q2 2012 Results - Earnings Call Transcript 08.14.12 | 07:08 pm
- 7 Stocks Under $10 Soaring Higher 05.24.12 | 12:05 pm
- 7 Stocks Soaring in a Weak Market 05.08.12 | 02:05 pm
- 8 Stocks Under $10 Making Big Moves 04.24.12 | 12:04 pm
- 7 Stocks Under $10 Moving Higher 11.16.11 | 12:11 pm
- 5 Drug Stock Losers of 2010 12.06.10 | 07:12 am
- Best and Worst Drug Stocks in Q3 10.01.10 | 08:10 am
- Biotech Stock Mailbag - Second Quarter Updates 08.13.10 | 07:08 am
Press Releases for VRML
- Vermillion's OVA1 Receives New Statement By Society Of Gynecologic Oncology - PR Newswire 06.11.13 | 08:06 am
- Vermillion Announces Closing Of Equity Financing - PR Newswire 05.14.13 | 08:05 am
- Vermillion Announces Equity Financing - PR Newswire 05.09.13 | 08:05 am
- Vermillion Supports First World Ovarian Cancer Day And Effort To Raise Awareness Of The Need For Better Diagnosis And Treatment - PR Newswire 05.08.13 | 04:05 pm
- Vermillion Sets First Quarter 2013 Conference Call For Wednesday, May 15, 2013 - PR Newswire 05.01.13 | 08:05 am
- U.S. Army And Vermillion To Assess Health And Economic Benefits Of OVA1 As A Standard Of Care - PR Newswire 04.17.13 | 08:04 am
- Vermillion Appoints Bruce A. Huebner To Chairman Of The Board - PR Newswire 03.19.13 | 08:03 am
- Vermillion Appoints Thomas McLain As President And Chief Executive Officer - PR Newswire 03.13.13 | 08:03 am
- Vermillion To Report Results For Fourth Quarter And Full Year 2012 On Wednesday, February 20, 2013 - PR Newswire 02.19.13 | 10:02 am
- Vermillion To Participate In Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference On February 27, 2013 - PR Newswire 02.19.13 | 08:02 am
Partner Headlines for VRML
- Mid-Day Market Losers - Benzinga 05.25.12 | 01:05 pm
- Morning Market Movers - Benzinga 03.27.12 | 09:03 am
- Mid-Sized Canadian Oil and Gas Companies Show How Hedging Pays Off - Seeking Alpha 07.21.11 | 09:07 am
- Top Percentage Gainers and Losers as of 2pm 05/13/11 (ABIO, GFRE, DDS, APL, DF, VRML, DAR, SWSH, ONTY, GS, RMBS, LPHI, GGS, CA, NVDA, IMRS, MNTX, MPG, GTY) - Benzinga 05.13.11 | 02:05 pm
- Vermillion Shares Climb 9% (VRML) - Benzinga 01.11.11 | 01:01 pm
- Vermillion Trading Up 27.47% Today (VRML) - Benzinga 12.27.10 | 01:12 pm
